고식적 위절제술을 받은 진행성 위암환자에서의 5-Fluorouracil , Adriamycin 및 Mitomycin ( FAM ) 3 제병용 화학용법의 효과 = The Effect of Combination Chemotherapy with 5-Fluorouracil , Adriamycin and Mitomycin ( FAM ) Following Palliative Resection for Advanced Gastric Carcinoma

다국어 초록 (Multilingual Abstract)

This study compared the survival of 41 patients who were treated with palliative resection followed by combination chemotherapy with 5-fluorouracil, adriamycin and mitomycin(FAM) to 31 patients treated only by palliative resection for advanced gastric carcinoma. The patients were serially collected from March 1982 to December 1984. The survival rate at 1 year was significantly higher in FAM treated group (FAM treated group, 63.6%, control group, 37,5%; p<0. 05), thereafter, patients treated with FAM, have shown continued tumor progression and death, and there was no significant survival difference at 2 nd year. Two year survival rate of 38 patients with stage IV treated with FAN was 31.4go, on the contrary, in control group, none of 25 patients survived at 2 year after resection(p<0.05). The median survival of FAM treated group was 12.3 months, and 10. 3 months in control group. The survival duration of stage IV, in FAM treated group(median, 13 months) was significantly longer than control group(median, 8.5 months). Acturial two year survival rate of the patients with microscopic residual disease, showed no significant difference between two treatment groups, However, at 2 years after resection, the patients with gross residual tumor, 32.0% in FAM treated group and none of control group survived(p<0. 05) The median survival period of the patients with microscopic residual tumor was 16 months in control group, of whom three of 12 patients were alive and 11 months in FAM treated group. But, in the patients with gross residual tumor, increased survival duration was observed in FAM treated group (median, 14. 1 months) than in control group(median, 7.3 months). In conclusion, FAM treatment significantly increased the survival period in patients with gross residual tumor and in stage g gastric cancer. But, some other forms of combined modality in addition with FAM would be needed for the further improvement in survival after palliative resection for advanced gestric carcinoma.